-
公开(公告)号:EA012437B1
公开(公告)日:2009-10-30
申请号:EA200701476
申请日:2006-01-26
Applicant: SERVIER LAB
Inventor: HURTEVENT NATHALIE , L HELGOUAL CH JEAN-MARTIAL , CARATO PASCAL , LEBEGUE NICOLAS , LECLERC VERONIQUE , BERTHELOT PASCAL , DACQUET CATHERINE , KTORZA ALAIN , CAIGNARD DANIEL-HENRI
IPC: C07D279/16 , A61K31/538 , A61K31/5415 , A61P3/06 , A61P3/10 , C07D265/36
Abstract: Соединенияформулы (I)вкоторой X представляетсобойатомкислородаилиатомсеры, R, R, Rи Rимеютзначения, указанныев описании, Апредставляетсобойалкиленовуюцепь, какопределенов описании, иВ представляетсобойалкильнуюилиалкенильнуюгруппу, замещеннуюгруппойили R, илиВ представляетсобойгруппуили R. Лекарственныесредства.
-
公开(公告)号:MA30795B1
公开(公告)日:2009-10-01
申请号:MA31791
申请日:2009-04-16
Applicant: SERVIER LAB
Inventor: MARCHAND PASCAL , BABONNEAU VINCENT , PIESSARD SYLVIE , DUFLOS MURIEL , BOUTIN JEAN ALBERT , AUDINOT VALERIE , DELAGRANGE PHILIPPE , CAIGNARD DANIEL-HENRI
IPC: C07D209/42 , A61K31/404 , A61P1/00 , A61P15/00 , A61P25/00 , A61P35/00 , A61P9/00
Abstract: COMPOSÉS DE FORMULE (I), DANS LAQUELLE R1 REPRÉSENTE UN GROUPEMENT ALKYLE, CYCLOALKYLE, OU CYCLOALKYLALKYLE; R2 REPRÉSENTE UN GROUPEMENT ALKYLE (C1-C6) LINÉAIRE OU RAMIFIÉ; ET N REPRÉSENTE 1 À 6, ET LEUR UTILISATION POUR TRAITER LES TROUBLES DU SYSTÈME MÉLATONINERGIQUE TELS QUE LES TROUBLES DU SOMMEIL, LE STRESS, L'ANXIÉTÉ, LES PATHOLOGIES CARDIOVASCULAIRES, ETC.
-
公开(公告)号:UA86801C2
公开(公告)日:2009-05-25
申请号:UAA200611437
申请日:2005-03-30
Applicant: SERVIER LAB , CENTRE NAT RECH SCIENT
Inventor: CASTEILLA LOUIS , PENICAUD LUC , BERTHELOT PASCAL , DACQUET CATHERINE , CAIGNARD DANIEL-HENRI
IPC: A61K31/428 , A61K9/20 , A61K31/15 , A61P3/04
Abstract: Комбинация, котораясодержитсоединение, котороеспособствуетметаболизмулипидови углеводов, иантиоксидантноевещество.
-
公开(公告)号:NO327257B1
公开(公告)日:2009-05-25
申请号:NO20043188
申请日:2004-07-27
Applicant: SERVIER LAB
Inventor: LECLERC VERONIQUE , RENARD PIERRE , CAIGNARD DANIEL-HENRI , CARATO PASCAL , PAILLOUX SYLVIE , INTROVIGNE CARINE , LEBEGUE NICOLAS , BERTHELOT PASCAL , DACQUET CATHRINE , BOUTIN JEAN ALBERT
IPC: C07D235/26 , C07D277/68 , A61K31/426 , A61K31/427 , A61P1/04 , A61P1/18 , A61P3/06 , A61P3/10 , A61P9/00 , A61P9/10 , A61P13/04 , A61P13/12 , A61P15/00 , A61P17/06 , A61P19/10 , A61P21/04 , A61P25/28 , A61P27/02 , A61P35/00 , C07D235/12 , C07D417/10 , C07D417/12
Abstract: Benzoxazole, benzothiazole or indole oxime derivatives (I) (including analogs with the benzo ring replaced by pyridine, pyrazine, pyrimidine or pyridazine) are new. Benzoxazole, benzothiazole or indole oxime derivatives of formula (I) (including analogs with the benzo ring replaced by pyridine, pyrazine, pyrimidine or pyridazine), and their enantiomers, diastereomers and salts are new. [Image] X : O, S, CH 2 or CHR' 2>; R 1>, R 2>H, alkyl, aryl, aralkyl, aryloxy, aralkoxy, alkoxy, OH, NH 2 or mono- or dialkylamino; or R 1> + R 2>=O, =S or =NH; R' 2>group forming an additional bond with R 2>; A : 1-6C alkylene (optionally having one CH 2 replaced by O, S, NRa', phenylene or naphthylene); Ra' : H or alkyl; R 3>, R 4>H, halo, R, OR or NRR'; or R 3> + R 4>group forming an ortho-fused 5- or 6-membered ring (optionally containing an O, S or N heteroatom); R, R', R 5>, R 6>H, alkyl, alkenyl, alkynyl, aryl, aralkyl, aralkenyl, aralkynyl, heteroaryl, heteroaralkyl, heteroaralkenyl, heteroaralkynyl, cycloalkyl, cycloalkylalkyl or polyhaloalkyl; D : benzene ring (in which case X is other than CHR' 2>); or a pyridine, pyrazine, pyrimidine or pyridazine ring; B : alkyl or alkenyl, both substituted by -CHR 7>R 8> or by R 9>; or -CHR 7>R 8> or R 9>; R 7>-C(Z)OR, -C(Z)NRR', -N(R)C(Z)R' or -N(R)C(Z)OR'; Z : O or S; R 8>aryl, aralkyl, heteroaryl, heteroaralkyl, CN, tetrazole, OR, NRR', -N(R)C(Z)R' or -N(R)C(Z)OR'; R 9>CN, tetrazole, -N(R)C(Z)R', -N(R)C(Z)OR' or -O(CH 2) n-CR 1> 0>R 1> 1>-COOR; n : 0-6; R 1> 0>, R 1> 1>H or alkyl, but not both H; aryl moieties : phenyl, naphthyl or biphenyl (all optionally partially hydrogenated and optionally substituted by 1-3 alkyl, polyhaloalkyl, alkoxy, OH, COOH, CHO, NRaRb, ester, amido, NO 2, CN or halo groups); heteroaryl moieties : 5-10 membered mono- or bicyclic aryl (where one ring is optionally partially hydrogenated in the case of bicyclic systems) containing 1-3 O, S and/or N heteroatom(s) and optionally substituted as for aryl; Rb, Rc : H, alkyl, aryl or heteroaryl; the oxime group -C(R 6>)=NOR 5> has E- or Z-configuration; alkyl moieties have 1-6C, alkenyl or alkynyl moieties 2-6C and cycloalkyl moieties 3-8C. Independent claims are included for: (1) preparation method of (I); and (2) new ketone intermediates of formula (V). [Image] ACTIVITY : Antidiabetic; Antilipemic; Cardiant; Nephrotropic; Ophthalmological; Antipsoriatic; Gynecological; Nootropic; Osteopathic; Antiinflammatory; Antiarteriosclerotic; Anorectic; Cytostatic. In tests in ob/ob mice, oral administration of 10 mg/kg of methyl 3-(4-(2-(6-((methoxyimino)-(phenyl)-methyl)-2-oxo-1,3-benzothiazol-3(2H)-yl)-ethoxy)-phenyl)-2-(2,2,2-trifluoroethoxy)-propanoate (Ia) twice per day for 4 days reduced blood sugar levels by 51% and reduced the weight gain by 80% in comparison with controls, whereas analogous administration of rosiglitazone reduced blood sugar levels by 61% but increased the weight gain by 33% in comparison with controls. MECHANISM OF ACTION : Aldose Reductase Inhibitor; Angiogenesis Inhibitor.
-
公开(公告)号:MX2007007900A
公开(公告)日:2009-02-16
申请号:MX2007007900
申请日:2007-06-27
Applicant: SERVIER LAB
Inventor: CAIGNARD DANIEL-HENRI , BERTHELOT PASCAL , DELAGRANGE PHILIPPE , MILLAN MARK , YOUS SAID , PERES BASILE , SABAOUNI AHMED , SPEDDING MICHAEL
IPC: C07C233/00 , C07C235/00 , C07C237/00 , C07C239/00
Abstract: La presente invención describe compuestos de fórmula (I) (ver fórmula (I)). Medicamentos.
-
公开(公告)号:MA30068B1
公开(公告)日:2008-12-01
申请号:MA31052
申请日:2008-06-19
Applicant: SERVIER LAB
Inventor: SUZENET FRANCK , GUILLAUMET GERALD , PILLARD CHRISTELLE , BASSENE CARINE , DACQUET CATHERINE , KTORZA ALAIN , CAIGNARD DANIEL-HENRI
IPC: C07D471/04 , A61K31/437 , A61P3/04 , A61P3/06
Abstract: Composés de formule (I). dans laquelle : X représente un atome d'hydrogène ou d'halogène, ou un groupement alkyle, R1, R2 , R3 et R4 sont tels que définis dans la description, A représente une chaîne alkylène telle que définie dans la description, B représente un groupement alkyle ou alkényle substitués par un groupement D représente un noyau pyridinique, comme agents hypoglycémiants et hypolipidémiants.
-
37.
公开(公告)号:MY136694A
公开(公告)日:2008-11-28
申请号:MYPI20041647
申请日:2004-04-30
Applicant: SERVIER LAB
Inventor: GRAINDORGE EMMANUEL , FRANCOTTE PIERRE , BOVERIE STEPHANE , TULLIO PASCAL DE , PIROTTE BERNARD , LESTAGE PIERRE , DANOBER LAURENCE , RENARD PIERRE , CAIGNARD DANIEL-HENRI
IPC: A61P25/18 , C07D513/04
Abstract: COMPOUNDS OF FORMULA (I): WHEREIN: A REPRESENTS A THIENYL, FURYL, PYRROLYL, OXATHIOL, THIAZOLE, ISOTHIAZOLE, OXAZOLE OR IMIDAZOLE GROUP, REPRESENTS A SINGLE BOND OR A DOUBLE BOND,R¹ REPRESENTS A HYDROGEN ATOM, A LINEAR OR BRANCHED (C₁-C6) ALKYL GROUP OPTIONALLY SUBSTITUTED BYONE OR MORE HALOGEN ATOMS, OR A (C₁-C6) ALKOXY-(C₁-C6)ALKYL GROUP, R₂ REPRESENTS A HYDROGEN ATOM OR A LINEAR OR BRANCHED (C₁-C6) ALKYL GROUP OPTIONALLY SUBSTITUTEDBY ONE OR MORE HALOGEN ATOMS, R₃ REPRESENTS A HYDROGEN ATOM OR A GROUP SELECTED FROM LINEAR OR BRANCHED (C₁-C6) ALKYL, CONHR''AND SO2NHR'' WHEREIN R'' REPRESENTS A LINEAR OR BRANCHED (C₁-C6) ALKYL GROUP, THEIR ENANTIOMERS AND DIASTEREOISOMERS, AND ALSO ADDITION SALTS THEREOF WITH A PHARMACEUTICALLY ACCEPTABLE ACID OR BASE.
-
公开(公告)号:HK1099689A1
公开(公告)日:2008-10-24
申请号:HK07106254
申请日:2007-06-12
Applicant: SERVIER LAB , CENTRE NAT RECH SCIENT
Inventor: CASTEILLA LOUIS , PENICAUD LUC , BERTHELOT PASCAL , DACQUET CATHERINE , CAIGNARD DANIEL-HENRI
IPC: A61K20090101 , A61K9/20 , A61K31/15 , A61K31/428 , A61P20090101
Abstract: A pharmaceutical composition for treatment of obesity associated with lipid and carbohydrate metabolism comprising (i) a substance which is useful in promoting lipid and carbohydrate metabolism, (ii) an antioxidant agent and, optionally, (iii) a pharmaceutically acceptable carrier or excipient, wherein the substance which promotes lipid and carbohydrate metabolism and the antioxidant agent are present in therapeutically effective dosages. Methods which are useful in treating conditions associated with obesity.
-
39.
公开(公告)号:AR061835A1
公开(公告)日:2008-09-24
申请号:ARP070103012
申请日:2007-07-06
Applicant: SERVIER LAB
Inventor: DACQUET CATHERINE , LECLERC VERONIQUE , L HELGOUAL CH JEAN-MARTIAL , LE NAOUR MORGAN , BERTHELOT PASCAL , LEBEGUE NICOLAS , CARATO PASCAL , KTORZA ALAIN , CAIGNARD DANIEL-HENRI
IPC: C07D277/68 , A61K31/428 , A61P3/04
Abstract: Reivindicacion 1: Compuestos de formula (1) en la que: R1 representa un átomo de hidrogeno y R2 y R3 forman junto con los 2 átomos de carbono adyacentes a los que están unidos un ciclo de formula (2) en el que R6 representa un átomo de hidrogeno o de halogeno, o un grupo alquilo C1-6 lineal o ramificado, alcoxi C1-6 lineal o ramificado, amino, alquilamino C1-6 lineal o ramificado, o dialquilamino C1-6 lineal o ramificado, X representa un átomo de oxígeno o un grupo N-OR7 en el que R7 representa un átomo de hidrogeno o un grupo alquilo C1-6 lineal o ramificado, arilo, o arilalquilo C1-6 lineal o ramificado, o R3 representa un átomo de hidrogeno y R1 y R2 forman junto con los 2 átomos de carbono adyacentes a los que están unidos un ciclo de formula (2) tal como se ha definido anteriormente, R4 y R5, idénticos o diferentes, representan un átomo de hidrogeno o de halogeno, o un grupo alquilo C1-6 lineal o ramificado, alcoxi C1-6 lineal o ramificado, amino, alquilamino C1-6 lineal o ramificado, o dialquilamino C1-6 lineal o ramificado, A representa una cadena alquileno C1-6 en la que un grupo CH2 puede reemplazarse por un heteroátomo elegido entre oxígeno o azufre, o por un grupo NRa (en el que Ra representa un átomo de hidrogeno o un grupo alquilo C1-6 lineal o ramificado), B representa un grupo alquilo C1-6) lineal o ramificado, o alquenilo C2-6 lineal o ramificado, estando sustituidos estos grupos con un grupo de formula (3) en la que R8 representa un grupo - COOR y R9 representa un grupo -OR' en el que R y R', idénticos o diferentes, representan cada uno un átomo de hidrogeno, o un grupo alquilo C1-6 lineal o ramificado no sustituido o sustituido con uno o varios átomos de halogeno, entendiéndose que: la oxima =N-OR7 puede tener configuracion Z o E, por arilo se entiende un grupo fenilo, naftilo o bifenilo, pudiendo estar estos grupos parcialmente hidrogenados, por heteroarilo se entiende cualquier grupo aromático mono o bicíclico que contiene 5 a 10 eslabones, pudiendo estar parcialmente hidrogenado en uno de los ciclos en el caso de los heteroarilos bicíclicos, y que contiene 1 a 3 heteroátomos elegidos entre oxigeno, nitrogeno y azufre, pudiendo estar sustituidos los grupos arilo y heteroarilo así definidos con 1 a 3 grupos elegidos entre alquilo C1-6 lineal o ramificado, polihalogenoalquilo C1-6 lineal o ramificado, alcoxi C1-6 lineal o ramificado, hidroxi carboxi, formilo, NRbRc (en el que Rb, y Rc, idénticos o diferentes, representan un átomo de hidrogeno, un grupo alquilo C1-6 lineal o ramificado, arilo o heteroarilo), éster, amido, nitro, ciano, o átomos de halogeno, sus enantiomeros y diastereoisomeros así como sus sales de adicion a un ácido o a una base farmacéuticamente aceptables.
-
40.
公开(公告)号:MY135191A
公开(公告)日:2008-02-29
申请号:MYPI20033845
申请日:2003-10-09
Applicant: SERVIER LAB
Inventor: RAULT SYLVAIN , LANCELOT JEAN-CHARLES , KOPP MARINA , CAIGNARD DANIEL-HENRI , PFEIFFER BRUNO , RENARD PIERRE , BIZOT-ESPIARD JEAN-GUY
IPC: A61P3/04 , A61P3/06 , A61P3/10 , A61P9/10 , C07D471/04
Abstract: COMPOUNDS OF FORMULA (I):WHEREIN: -R1 REPRESENTS A HYDROGEN ATOM, A HALOGEN ATOM OR AN ALKYL,POLYHALOAKYL, CYANO, NITRO, HYDROXYCARBONYL, ALKOXYCARBONYL, AMINOCARBONYL, ALKYLAMINOCARBONYL OR DIALKYL-AMINOCARBONYL GROUP, -R2 REPRESENTS A HYDROGEN ATOM, AN ALKYL GROUP, AN OPTIONALLY SUBSTITUTED ARYL GROUP, AN OPTIONALLY SUBSTITUTED HETEROARYL GROUP, OR A GROUP R20-C(X)-WHEREIN: > R20 REPRESENTS AN ALKYL GROUP, AN ALKOXY GROUP, AN AMINO GROUP, AN ALKYLAMINO GROUP, A DIALKYLAMINO GROUP, AN OPTIONALLY SUBSTITUTED ARYL GROUP OR AN OPTIONALLY SUBSTITUTED HETEROARYL GROUP, > X REPRESENTS AN OXYGEN ATOM, A SULPHUR ATOM, OR A GROUP NR21 WHEREIN R21 REPRESENTS A HYDROGEN ATOM OR AN ALKYL GROUP, -R3 REPRESENTS A HYDROGEN ATOM OR AN ALKYL GROUP, -N REPRESENTS AN INTEGER FROM 1 TO 6 INCLUSIVE, -THE REPRESENTATION R1 MEANS: FORMULA THEIR ENANTIOMERS,DIASTEREOISOMERSAND ALSO ADDITION SALTS THEREOF WITH A PHARMACEUTICALLY ACCEPTABLE ACID OR BASE.MEDICAMENTS.
-
-
-
-
-
-
-
-
-